Cost-utility assessment of amifostine as first-line therapy for ovarian cancer

C. L. Bennett, R. M. Golub, E. A. Calhoun, J. Weinstein, D. Fishman, J. Lurain, P. Roland, F. Medio, R. M. Bukowski

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-utility assessment of amifostine as first-line therapy for ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences